BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 32142770)

  • 21. Valproate attenuates the proteinuria, podocyte and renal injury by facilitating autophagy and inactivation of NF-κB/iNOS signaling in diabetic rat.
    Khan S; Jena G; Tikoo K; Kumar V
    Biochimie; 2015 Mar; 110():1-16. PubMed ID: 25572918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
    Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
    Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
    Ellis L; Lehet K; Ramakrishnan S; Adelaiye R; Miles KM; Wang D; Liu S; Atadja P; Carducci MA; Pili R
    PLoS One; 2011; 6(11):e27178. PubMed ID: 22087262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Britannin, a sesquiterpene lactone induces ROS-dependent apoptosis in NALM-6, REH, and JURKAT cell lines and produces a synergistic effect with vincristine.
    Mohammadlou H; Hamzeloo-Moghadam M; Mohammadi MH; Yami A; Gharehbaghian A
    Mol Biol Rep; 2021 Sep; 48(9):6249-6258. PubMed ID: 34478011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.
    Beagle BR; Nguyen DM; Mallya S; Tang SS; Lu M; Zeng Z; Konopleva M; Vo TT; Fruman DA
    Oncotarget; 2015 Feb; 6(4):2088-100. PubMed ID: 25576920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.
    Maiso P; Colado E; Ocio EM; Garayoa M; Martín J; Atadja P; Pandiella A; San-Miguel JF
    Leukemia; 2009 Dec; 23(12):2265-74. PubMed ID: 19812608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
    Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
    Karthik S; Sankar R; Varunkumar K; Anusha C; Ravikumar V
    Biomed Pharmacother; 2015 Feb; 69():337-44. PubMed ID: 25661379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia.
    Toosi B; Zaker F; Alikarami F; Kazemi A; Teremmahi Ardestanii M
    Biomed Pharmacother; 2018 Jun; 102():428-437. PubMed ID: 29574283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B1, a novel HDAC inhibitor, induces apoptosis through the regulation of STAT3 and NF-κB.
    Cheng MH; Wong YH; Chang CM; Yang CC; Chen SH; Yuan CL; Kuo HM; Yang CY; Chiu HF
    Int J Mol Med; 2017 May; 39(5):1137-1148. PubMed ID: 28393178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
    Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B
    BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.
    Noack K; Mahendrarajah N; Hennig D; Schmidt L; Grebien F; Hildebrand D; Christmann M; Kaina B; Sellmer A; Mahboobi S; Kubatzky K; Heinzel T; Krämer OH
    Arch Toxicol; 2017 May; 91(5):2191-2208. PubMed ID: 27807597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer.
    Chen E; Liu N; Zhao Y; Tang M; Ou L; Wu X; Luo C
    Gene; 2022 Jan; 808():145977. PubMed ID: 34592353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.
    Rosato R; Hock S; Dent P; Dai Y; Grant S
    Leuk Res; 2012 Apr; 36(4):491-8. PubMed ID: 22074700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
    Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
    Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells.
    Kanno S; Maeda N; Tomizawa A; Yomogida S; Katoh T; Ishikawa M
    Int J Oncol; 2012 May; 40(5):1391-6. PubMed ID: 22211246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.